BioSpace News Archive

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will host a virtual event on Tuesday, June 28, 2022 at 9:00 AM EDT/

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 2,500,000 shares of Series A convertible redeemable preferred stock and 500,000 shares of Series B convertible redeemable preferred stock.

Alpha Cognition Inc. today announced positive results from its pivotal bioequivalence study with ALPHA-1062, a proprietary, delayed release oral tablet formulation in development for the treatment of mild to moderate Alzheimer’s Disease (AD).

mRNA-1273.214 Exhibited a Greater Than 5-Fold Boost in Neutralizing Antibodies Against BA.4 and BA.5 Subvariants in Phase 2/3 Study.

These results are the first reported demonstration of rapid and robust treatment changes in key disease markers associated with the severity of disease.

Wilmington, Delaware, United States: The global clinical decision support system market was valued at US$ 1.2 Bn in 2021.

The global automated radiosynthesis modules market is forecasted to be a million-dollar opportunity for industry participants expected to be encouraged by a colossal demand in the recent years.

Wilmington, Delaware, United States: 5G is the fifth generation of cellular wireless technology, which can offer massive connection power and fast internet speed for data transfer.

The world structural heart devices market has recently witnessed the best of collaborations yet.

Devyser has been awarded a tender from Héma-Québec, in Québec, Canada, for its non-invasive fetal RHD detection product, used to determine fetal RHD status from maternal plasma in early pregnancy.